Press Release
Pheonix Research Releases 2026–2033 IV Sterile Compounding Automation Forecast: USD 2.75 Billion by 2033, With 225 of 6,093 US Hospitals Automated Today
FOR IMMEDIATE RELEASE
18 November 2026 — Pheonix Research today publishes its first full study of the IV and sterile compounding automation market, sizing global market value at USD 940.0 million in 2025 and forecasting USD 2,752.0 million in 2033 — a compound annual growth rate of 14.37 per cent, or USD 1,812.0 million of new value.
The finding that matters commercially is the arithmetic underneath the growth rate. Systems shipped rise from 4,820 to 13,700 over the period, 13.95 per cent a year, while revenue per system moves only from USD 195,021 to USD 200,803 — 0.37 per cent a year. Value grows almost exactly as fast as unit count. There is no price story in this market at all; every point of growth is another room converted.
“Penetration in this category is capped by volume per site, not by product availability,” said the Pheonix Research healthcare devices team. “Consolidation, not a cheaper robot, is what unlocks robotics. When a health system moves compounding from twelve rooms into two, it multiplies the volume each surviving site handles by six, and the payback that failed at 20,000 doses starts working at 120,000.”
Key findings
- The room is instrumented long before it is automated. Of 6,093 US hospitals, 225 use any automation for compounding sterile preparations — 3.7 per cent — and 177 use a sterile compounding robot, or 2.9 per cent. Meanwhile 3,266 scan their ingredients and 2,352 photograph the process.
- The constraint is a payback test, not a technology gap. At the US median pharmacy technician wage of USD 43,460, three and a half minutes of technician time per dose is worth USD 1.22 at wage and about USD 1.65 loaded. At 70,000 doses a year against a USD 1.2 million platform, the annual saving is USD 115,213 — a 10.4-year payback. A USD 95,000 verification deployment saving one minute across 40,000 doses returns USD 18,812 and pays back in 5.05 years. Same room, half the exposure.
- The leading compounding platform has reached roughly one hospital in six after thirty years. Baxter’s ExactaMix has been sold for more than three decades and is used by more than 1,000 hospital pharmacies and compounding centres, compounding over 100 million bags. That is roughly 3,333 bags per site per year — nine a day.
- USP <797> raised the cost of the room, not the case for the robot. The revised chapter, official since 1 November 2023, removed the low-volume provision outside a negative pressure space, required two tiers of containment, and assigned accountability for facility, personnel and process. A hospital that has just funded compliance has no budget left for a robot in the same cycle.
- Only 18.3 per cent of the market traces to a named vendor pool. That is USD 172 million of the 2025 base, and all of it is allocated rather than disclosed, because no vendor reports IV compounding automation as a segment. The remaining 81.7 per cent is a bottom-up estimate, labelled as such.
The technology itself is not in doubt. ARxIUM’s RIVA platform has compounded more than one million doses across two systems at the Prinses Máxima Centrum since 2018. What limits the category is what surrounds the machine: cleanroom capital, floor space, gravimetrics sitting at 7.7 per cent of the installed base because it is a formulary data project rather than a scale, and the fact that a pharmacy cannot stop dispensing while it is rebuilt.
The 503B corridor, and the assumption that carries the forecast
The FDA’s outsourcing-facility framework gives health systems a way to buy compounded sterile preparations instead of making them — a corridor of 93 registered facilities rather than an exit from the room. The report states its own weakest input plainly: the 0.37 per cent realisation. At plus 2.5 per cent, 2033 value is USD 3,255.3 million; at minus 2.0 per cent, USD 2,273.1 million.
Report details
- Title: Global IV Sterile Compounding Automation Market Report, Size, Share and Forecast 2026–2033: Thirty Years In, One Hospital in Six, and a Robot That Takes a Decade to Pay Back
- Base year and horizon: 2025 base, forecast to 2033.
- Coverage: global, by system class — robotic IV compounders, gravimetric and volumetric compounding, workflow and verification software, remote pharmacist verification, and consumables — across hospital central pharmacy, satellite and decentralised sites, and 503B outsourcing facilities.
- Chapters: market sizing and forecast; value chain and cost structure; technology and innovation; competitive landscape; investment activity; market risk and scenarios; regulatory landscape covering USP <797> and <800>, FDA 503B mechanics, and device status.
- Methodology: a 70/30 split of secondary and primary research. Primary work covers price bands, payback arithmetic, the specification chain and switching behaviour; market size is modelled from secondary disclosure. No market-research competitor data is used as an input.
- Available at: pheonixresearch.com/healthcare/medical-devices/market-report/global-iv-sterile-compounding-automation-market/
About Pheonix Research
Pheonix Research is a market intelligence platform that queries a live graph of more than 500 market nodes to surface leading signals and translate them into role-specific decisions. It publishes market reports across industrial, healthcare and technology sectors, built from disclosed primary sources, a structured primary research programme, and a documented model in which every estimated figure is identified as an estimate.
Media contact
Pheonix Research
Research & Intelligence: [email protected]
Sales & Engagements: [email protected]
Website: www.pheonixresearch.com
— Ends —
